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Abstract
Neglected tropical diseases are a group of infectious diseases caused by infectious and 
parasitic agents that occur in a large part of the world affecting millions of people and can 
complicate matters with serious organ damage. The kidneys can be affected in many of 
these diseases, including Chagas disease, dengue, leishmaniasis, leprosy, and schistoso-
miasis. In this chapter, we describe the mechanisms by which the kidneys are damaged 
in the setting of these diseases, the clinical manifestations, and the current available treat-
ment options. We also describe the recent novel biomarkers that are under investigation 
for the early diagnosis of kidney injury in the course of these diseases and the future 
perspectives.
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1. Introduction
The World Health Organization (WHO) lists a group of communicable diseases that currently 
affects more than one billion people in more than 100 countries and cost billions of dollars 
every year [1]. These diseases have the common characteristics of affecting predominantly 
poor people living in precarious conditions, with close contact with vectors and domestic 
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animals, and also facing difficulties to access health-care facilities. The 2018 WHO list of 
neglected tropical diseases includes Buruli ulcer, Chagas disease, dengue, chikungunya, 
dracunculiasis, echinococcosis, foodborne trematodiases, human African trypanosomiasis, 
leishmaniasis, leprosy, onchocerciasis, rabies, scabies and other ectoparasites, schistosomia-
sis, soil-transmitted helminthiases, snakebite envenoming, taeniasis/cysticercosis, trachoma, 
yaws, lymphatic filariasis, mycetoma, chromoblastomycosis, and other deep mycoses [1]. 
The kidneys are frequently affected in these diseases, and in some cases, the complications 
increase the risk of death. In this chapter, we discuss the main neglected tropical diseases, 
which complicate matters with kidney involvement.
2. Chagas disease
Chagas disease (or American trypanosomiasis) is the infection caused by the flagellated pro-
tozoan Trypanosoma cruzi and transmitted by insects of the family Triatominae, the Triatoma 
infestans, known as “kissing bugs” (in Brazil: “barbeiro”; in Argentina, Bolivia, Chile, and 
Paraguay: “vinchuca”; in Colombia: “pito”; in Venezuela: “chipo”; and in Central America: 
“chinche”) [2]. The transmission occurs through the inoculation of T. cruzi in the blood of 
the host, through the insect stool left next to the site of the bites. The infection can also occur 
through the ingestion of the infected insects (contaminated food), blood transfusion, organ 
donation, or vertical transmission [3]. Kidney involvement in Chagas disease is seldom 
described and rarely studied [4].
The disease is endemic in 21 Latin American countries, and the highest prevalence is regis-
tered in Bolivia, Argentina, Paraguay, Ecuador, El Salvador, and Guatemala [3]. In Brazil, 
there was a significant decrease in incidence due to the vector control program, and now the 
disease is predominantly seen as chronic cases with cardiac or gastrointestinal manifestations 
[5, 6].
Clinical manifestations of Chagas disease can be divided into acute and chronic phase [3, 4]. 
The acute phase manifests with fever, signs of inflammation at the inoculation site, unilateral 
palpebral edema (Romaña sign), lymphadenopathy, and hepatosplenomegaly [3]. Severe 
acute Chagas infection is rare and occurs in less than 5% of the cases, manifesting with acute 
myocarditis, pericardial effusion, and meningoencephalitis [3]. The chronic phase develops 
in 10–30% of infected individuals and is characterized by heart disease and gastrointestinal 
disease (megaesophagus and megacolon) [7, 8].
T. cruzi has the ability to act as a parasite to a great variety of cells, including kidney cells [4]. 
There is evidence of functional and structural kidney abnormalities after T. cruzi infection, 
associated with reduction in renal blood flow, proximal tubular damage, and inflammatory 
interstitial infiltrate. An observation is made of an increased production of pro-inflammatory 
cytokines and nitric oxide, as well as renal function loss associated with high parasitic load 
[9–12]. In the acute phase, the renal lesion is related to cardiovascular dysfunction, due to 
a transitory decrease in renal blood flow, which was demonstrated in experimental mod-
els [11, 13]. Glomerulonephritis is reported in T. cruzi infection and also demonstrated in 
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experimental studies [14, 15]. The pathophysiology of kidney involvement in Chagas disease 
is associated with immunological process and includes autoantibodies production [16, 17]. 
There are reports that in the chronic phase of the disease, glomerular deposits of IgM occur 
at early stages, with intense inflammatory response, resulting in immune complex formation, 
which leads to glomerulonephritis [9]. The exact mechanism by which T. cruzi causes kidney 
disease is still to be elucidated [4].
Treatment of Chagas disease is based on antitrypanosomal drugs, which is indicated for all 
acute and congenital cases, reactivated cases, and chronic disease in individuals <18 years [3]. 
Specific treatment is currently recommended even for patients with the chronic forms of the 
disease, despite achieving lower cure rates than in acute phase [6]. The main available drugs 
are benznidazole (dose for adults: 5 mg/kg/day; for children: 5–10 mg/kg/day) and nifurtimox 
(dose for adults: 8–10 mg/kg/day; for children: 15 mg/kg/day), for 60 days.
3. Dengue and other endemic arbovirosis
Dengue is the most common arbovirosis in the world, there are more than 2 billion people 
living in endemic areas [18], and it is the second most common disease transmitted by mos-
quitoes, following malaria [19]. Tropical countries face repeated outbreaks of the disease. In 
Brazil, the most recent outbreaks have affected millions of people [20, 21]. In recent years, 
other arbovirosis has caused epidemics in the Caribbean region and Latin America: chikungu-
nya fever and Zika virus infection, and renal involvement has already been reported [22–27].
Clinical manifestations vary according to patients’ age, and the incubation period varies from 
3 to 14 days. The majority of patients are asymptomatic or have a mild disease characterized 
by fever, headache, myalgia, arthralgia, retroorbital pain, and maculopapular rash, which has 
been known as dengue fever [19, 28]. Severe forms of the disease, characterized by coagu-
lation disturbances, increased vascular permeability, and hemorrhagic manifestations, are 
classically known as dengue hemorrhagic fever and can evolve to dengue shock syndrome 
[19]. There is evidence that severe cases of dengue are increasing, complicating with organ 
damage, including kidney involvement [14, 18].
Renal abnormalities in dengue include hydroelectrolyte disturbances, acute kidney injury 
(AKI), and, less frequently, glomerulonephritis, rhabdomyolysis, and hemolytic uremic syn-
drome [18, 29–31]. AKI seems to be more frequent in adults than in children with dengue 
and is associated with hypotension, sepsis, multiple organ dysfunction, and use of vasoactive 
drugs [30–37]. Direct kidney damage caused by dengue virus is described through cytopathic 
effect of viral proteins on glomerular and tubular cells, associated with immunological mech-
anisms mediated by viral antigens deposited on glomerular structures and tissue damage by 
immune complex deposition [18, 31, 38]. Other factors that mediate renal lesions in Dengue 
are hemodynamic instability, hemolysis, rhabdomyolysis, and nephrotoxic drug use. Autopsy 
studies show evidence of acute tubular necrosis, predominantly in the proximal tubules, hem-
orrhage, and edema, more accentuated in the medullary region [29, 38]. Dengue-associated 
AKI usually has a favorable outcome, with recovery in around 2 weeks [18]. Among patients 
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with chronic kidney disease, dengue is associated with high mortality [18]. Among renal 
transplant patients, dengue fever also presents favorable outcomes and does not significantly 
affect the allograft function [39].
Chikungunya infection is another arbovirosis that has been responsible for large epidemic in 
recent years, causing self-limited disease in most cases, with predominant symptoms being 
fever and arthralgias [22, 23], but renal involvement has been reported in fatal cases [22, 24]. 
A series of 10 autopsies from Colombia evidenced that renal involvement is frequent, with 
serum creatinine at admission varying from 1.2 to 8.9 mg/dl (median 2.8 mg/dl), and the 
main histopathological findings were glomerular involvement (glomerular edema, nephro-
sclerosis, and membranoproliferative glomerulonephritis) and acute tubular necrosis [22, 24]. 
Similar to what is seen in dengue infection, transplanted patients who acquire Chikungunya 
infection seem to have a milder disease, with less severe arthralgia, and this could be due to 
immunosuppressant drug effects [25]. The acute viral infection also seems not to significantly 
affect the renal allograft [25].
Zika is another arbovirosis that usually causes a mild infection, which is predominated by fever, 
arthralgias (milder than in dengue and chikungunya), and a typical rash with pruritus, which 
was brought to the attention of the Public Health authorities in 2015—the outbreak occurred 
in Brazil affecting a large number of people and causing neurologic disturbances in newborns, 
including microcephaly [26, 27]. Renal involvement has been recently described in experimen-
tal studies, which demonstrated that the Zika virus has the potential to infect different types 
of kidney cells, including podocytes, endothelial and mesangial cells, and the virus can also be 
detected in the urine, which is an evidence of the kidneys as reservoirs of the virus and a poten-
tial source for the transmission [26, 27]. These findings also suggest that patients infected with 
Zika virus are at risk of developing glomerulonephritis, as expected in the other arbovirosis.
There is no specific treatment for dengue, as well as for the other arbovirosis, so it consists 
in supportive measures and depends on clinical manifestations [40]. Treatment basis include 
hydration (oral or venous, depending on disease severity), resting and symptomatic medica-
tion (antipyretics, analgesics), and avoiding the use of anti-inflammatory drugs. Correction of 
metabolic and electrolyte disturbances is crucial and if instituted early can prevent complica-
tions [18]. Dengue vaccines are under research and the available ones present good results in 
individuals with previous exposure to the virus [41].
4. Leishmaniasis
Leishmaniasis is the tropical disease caused by the parasites from the genus Leishmania, trans-
mitted by mosquitoes Phlebotomus and Lutzomyia, with the majority of cases concentrated in 
Latin America, South East Asia, East Africa, and, less frequently, Europe [42, 43]. There are 
12–15 million infected people in the world, and 350 million are at risk [43]. Approximately, 
1.5 –2 million new cases of leishmaniasis are registered in the world each year [43], and 90% 
of cases are concentrated in India, Ethiopia, Somalia, Sudan, and Brazil [44–46].
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The disease can be asymptomatic or manifest as a localized disease in the skin (cutaneous 
leishmaniasis) or affect different organs (visceral leishmaniasis, also known as kala-azar or 
black fever). Incubation period can vary from few weeks to years, and the main symptoms 
and signs include insidious low-grade fever, pallor, splenomegaly, hepatomegaly, fatigue, 
weakness, hyporexia, and weight loss [42, 47]. In endemic areas, such as northeast of Brazil, 
the most affected individuals with visceral leishmaniasis are children [28]. Laboratory abnor-
malities are common and are typically characterized by pancytopenia, associated with hyper-
globulinemia and hypoalbuminemia [28].
Kidney involvement in visceral leishmaniasis has been studied in both cutaneous form of 
leishmaniasis (American cutaneous leishmaniasis), in which tubular dysfunction predomi-
nates [48], and visceral leishmaniasis, in which renal lesions seem to be more frequent and 
severe [49]. Immunological mechanisms seem to be the key components of kidney injury in 
leishmaniasis, with immune complex deposition, T cell activation, and inflammatory process, 
leading to glomerulonephritis and interstitial nephritis [49–51]. Clinically, renal involvement 
in visceral leishmaniasis can manifest with acute kidney injury (AKI), mild-to-moderate pro-
teinuria, hematuria, leukocyturia, hydroelectrolyte disturbances, and tubular defects—uri-
nary concentration and acidification defects, which can persist even after specific treatment 
[52–54]. Glomerular disease in leishmaniasis is characterized to be mesangial proliferative, 
with immune complex deposition, and can complicate with rapidly progressive glomerulo-
nephritis [55, 56]. Microalbuminuria is the most frequent renal abnormality found in patients 
with visceral leishmaniasis (around 40%), evidencing important glomerular filtration barrier 
defect caused by the infection process [57, 58]. AKI has also been reported in a considerable 
number of patients (more than 30%); it seems to be more frequent and severe in adults and 
is associated with hypokalemia, leukopenia, and use of amphotericin B [53, 59]. AKI was also 
associated with hyponatremia, hypoalbuminemia, hyperglobulinemia, and secondary infec-
tions in children with visceral leishmaniasis [60]. New biomarkers are under investigation 
aiming to detect early kidney injury in tropical diseases, including leishmaniasis. The most 
studied by now are the neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule-1 (KIM-1), and monocyte chemotactic protein-1 (MCP-1) [61–63]. NGAL has been 
associated with AKI in visceral leishmaniasis, presenting good accuracy for the early diagnosis 
of AKI, and is a promisor tool for the identification of patients at risk of developing severe 
disease [64].
Treatment consists of anti-Leishmania drugs, and the standard treatment is pentavalent anti-
monials [42, 43]. The most commonly used drug is meglumine, but the biggest problem is its 
toxicity (cardiotoxicity). The second choice is amphotericin B, which has nephrotoxicity as the 
main adverse effect [42, 43].
5. Leprosy
Leprosy is a chronic disease caused by the Mycobacterium leprae, an acid-fast bacillus, charac-
terized to be incapacitating and to cause organ failure in some cases, including kidney disease 
Neglected Tropical Diseases with an Impact on Kidney Function
http://dx.doi.org/10.5772/intechopen.78981
35
[49, 65, 66]. The disease is highly contagious, but few people develop the disease once there 
is natural resistance to the bacillus [65]. This is one of the oldest diseases known to affect 
humankind, with reports in the Bible [67].
There are reports of leprosy in 138 countries, with world prevalence of 0.2 cases per 10,000 
inhabitants in 2015 [68]. The number of new cases in this same year was 211,973 cases, evi-
dencing continued transmission (2.9 cases per 100,000 inhabitants). India and Brazil are 
responsible for the highest majority of cases in the world [68].
The spectrum of manifestations depends on the host’s immunity and response to M. leprae, 
and the incubation period is long, going from 6 months to 10–20 years [65, 66]. During the 
course of the disease, there are “reactional states,” in which the immune system reacts against 
the bacilli, exacerbating the clinical manifestations. The disease can be classified as paucibacil-
lary and multibacillary, according to the number of skin lesions and bacilli found in skin 
smears [65, 66]. Besides affecting the skin, leprosy characterizes to cause peripheral nerve 
damage [65] and can complicate with systemic involvement, including nephropathy [49].
Kidney involvement in leprosy has been described for the first time a long time ago in autopsy 
studies and includes different types of glomerular lesions, such as epithelioid granulomas, and 
also Hansen’s bacillus in renal parenchyma [49]. It is found in all forms of the disease but is 
more frequent in multibacillary forms [69, 70]. The most common leprosy-associated glomer-
ular disease is mesangial proliferative glomerulonephritis and other histologic types are also 
found: acute proliferative glomerulonephritis, membranous glomerulonephritis, rapidly pro-
gressive glomerulonephritis, and others. Chronic tubulointerstitial nephritis and amyloidosis 
have also been described in the course of leprosy, leading to chronic kidney disease [71, 72]. 
The mechanics by which M. leprae infection leads to kidney disease are not completely 
understood [49], and it is probably associated with immunological phenomena. Complement 
reduction and immune complex deposition in glomerular basement membrane have been 
described [73–75]. Oxidative stress also plays a role in leprosy nephropathy. There is evidence 
of subclinical kidney damage even in patients with controlled infection. The levels of urinary 
MCP-1 are increased in leprosy patients and are associated with microalbuminuria levels and 
amount of bacilli of skin smears [76]. Renal tubular disturbances have also been described 
in leprosy, including concentration and acidification defects [77]. AKI can also occur in lep-
rosy and seems to be associated to glomerulonephritis complications or secondary to the use 
of nephrotoxic drugs, mainly anti-inflammatory drugs and rifampicin, which are used in 
leprosy therapeutic scheme. Leprosy nephropathy seems to have changed in recent years, 
becoming a milder disease, characterized by micro-hematuria and mild proteinuria, which 
tends to recover after specific treatment [78].
Treatment consists of specific multi-drug therapy, reactional state treatment, prevention of 
disabilities, and psychosocial support. Specific therapy includes rifampicin and dapsone for 
paucibacillary patients (for 6 months) and rifampicin, dapsone, and clofazimine for multi-
bacillary patients (for 12 months). Corticosteroids may be used for reactional states. Leprosy-
associated end-stage kidney disease may require renal replacement therapy, which includes 
dialysis or transplantation, and immunosuppression for renal transplanted patients seems 
not to alter the response to leprosy-specific treatment [49].
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6. Schistosomiasis
Schistosomiasis is the parasitic disease caused by organisms of the genus Schistosoma, which 
affects more than 200 million people in the world and is endemic in some tropical areas of 
the globe [79, 80]. It is the second most frequent parasitic disease, after malaria, and is still an 
important infection-associated cause of death [81].
The definitive host is the men, where the adult parasite reproduces and eliminates its eggs, 
which contaminated water resources [79]. In nature, disease transmission depends on the 
presence of snails from the family Planorbidae and genus Biomphalaria, and the men acquire 
the infection when the cercariae penetrate through the skin. The presence of the parasite in the 
human organism is relatively harmless, and the manifestations depend on immune response 
to different stages of the parasite in the body [82]. The disease can manifest as an acute 
syndrome, also known as Katayama syndrome, which is more common among travelers or 
immigrants in endemic areas with no immunity to Schistosoma and is characterized by fever, 
malaise, myalgia, headache, and abdominal pain, which can last from 2 to 10 weeks [80]. 
Depending on the patient’s immune system response, the disease can progress to the chronic 
forms, in which predominate the intestinal form, in the case of S. mansoni, S. japonicum and S. 
mekongi infections. Patients with poor immune regulation develop severe fibrosis and hepa-
tosplenic disease with periportal fibrosis [80]. The species S. haematobium, which occurs in 
some parts of Africa, affects the urogenital system, manifesting mainly by hematuria [80–82]. 
Other symptoms described in the infection by S. haematobium include hematospermia and 
inflammation in other structures in men—epididymis, testicles, spermatic cord and prostate, 
and women—hypertrophic/ulcerative lesions of the vulva, vagina, and cervix [82].
Kidney involvement in schistosomiasis is described and predominates in the form of glomeru-
lonephritis [79]. In schistosomiasis, there are circulating antigens of adult parasite, and its eggs 
can be found in different organs, including the kidneys [79]. Acute kidney injury (AKI) is also 
described, with high prevalence in endemic areas, affecting as high as more than 40% of patients 
with the chronic forms of the disease [79]. Schistosomal glomerulonephritis is classically associ-
ated with the hepatosplenic form and ranges from asymptomatic disease to nephrotic syndrome 
[79]. Renal histopathological analysis evidences immune complex deposition, with schistosomal 
antigens in the glomerular basement membrane, as well as the presence of schistosomal eggs 
and granulomas. The mechanism of these lesions includes immunological phenomena, with 
response directed against parasite’s antigens and immune complex formation and deposition in 
the glomeruli [83–86]. There is also evidence of polyclonal B-lymphocytes activation [87], but it 
is not sufficient to induce the process of nephritis, so more recent studies suggest the participa-
tion of autoimmune mechanisms [88]. The most common pattern of glomerular disease in schis-
tosomiasis is mesangial proliferative and membranoproliferative glomerulonephritis [89, 90]. 
There are deposits of IgM, IgG, and C3 [91]. Amyloidosis has also been described [79, 92] but is 
less frequent, although it is always a possible pattern of kidney disease in any infectious disease 
with chronic evolution. Schistosomal glomerulonephritis can be classified in five types: mesan-
gial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, focal and 
segmental glomerulosclerosis, exudative glomerulonephritis, and amyloidosis [91]. Granuloma 
formation in the kidney is also a possible but rare complication of schistosomiasis [92]. Tubular 
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dysfunction also occurs in schistosomiasis, mainly urinary concentration dysfunction, which 
can be found in as high as 85% of patients with the hepatosplenic form in endemic areas [93]. 
Even in patients infected with S. mansoni, without clinically significant disease, there is evidence 
of renal inflammation, which was shown through increased urinary levels of MCP-1 [94].
Treatment is based on specific drugs, the first choice being praziquantel [80, 82], which has 
action against all Schistosoma species and provides cure rates above 80% [82]. The recom-
mended dose is 40 mg/kg for S. haematobium and S. mansoni, and 60 mg/kg for S. japonicum [82].
Table 1 summarizes the main aspects of kidney involvement in the neglected tropical diseases 
discussed in this chapter.
Figure 1 illustrates the general pathophysiology of kidney involvement in tropical infectious 
and parasitic diseases.
Disease AKI CKD Histopathological features Novel biomarkers
Chagas Yes Probable, 
associated 
with cardiac 
involvement and 
heart failure
Deposits of IgM, IgG, C3, 
mesangial deposits, renal 
infarction, tubulointerstitial 
damage, renal infarction
—
Dengue Yes Rare Deposits of IgM, IgG, C3, 
and less frequently IgA, 
acute tubular necrosis, 
glomerulonephritis
—
Leishmaniasis Yes, associated 
with drugs, 
mainly 
amphotericin B
Possible, 
associated with 
amyloidosis 
and other 
complications
Deposits of IgM, IgG, 
C3, different types of 
glomerulonephritis, most 
common: mesangial and 
membranoproliferative, 
tubulointerstitial lesions, 
amyloidosis, tubular 
dysfunction
NGAL, early predictor 
of AKI, associated with 
microalbuminuria
Leprosy Yes Possible, 
associated with 
amyloidosis 
and other 
complications
Deposits of IgM, IgG, 
C3, different types of 
glomerulonephritis, 
mainly mesangial and 
membranoproliferative, but 
also rapidly progressive 
glomerulonephritis, 
tubulointerstitial nephritis, 
amyloidosis, tubular 
dysfunction
MCP-1, associated with 
renal inflammation
Schistosomiasis Yes Not common Deposits of IgM, IgG, 
C3, different types of 
glomerulonephritis, 
mainly mesangial and 
membranoproliferative, 
amyloidosis, tubular 
dysfunction
MCP-1, associated with 
renal inflammation
AKI: acute kidney injury; CKD: chronic kidney disease; NGAL: neutrophil gelatinase-associated lipocalin; MCP-1: 
monocyte chemoattractant protein-1.
Table 1. Kidney involvement in neglected tropical diseases.
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7. Conclusion
Neglected tropical diseases represent a global public health problem, affecting billions of 
people and requiring billions of dollars to treat and control. Authorities should have in 
mind that the key approach to these diseases, including kidney disease itself, is preven-
tion, which is far from ideal, mainly in the developing world. Governments should also 
have in mind that the main determinant factors for the perpetuation of the neglected tropi-
cal diseases in the world in the sum of poor living conditions (lack of sanitation, potable 
water, piped water, garbage collection, education, domestic animal control, disease-vector 
control, environmental problems, lack of urbanization plans, and many others), and they 
have responsibility for the control of these diseases [95]. Many complications can arise 
from these diseases, and one of the most frequent and severe is kidney disease. The main 
pathophysiologic factors include immunological phenomena and hemodynamic abnor-
malities. Endemic diseases, such as dengue, chikungunya, and Zika virus infection, which 
have affected millions of people in the last few years, are having increasing evidences of 
kidney involvement in severe cases. In the majority of cases, kidney involvement in these 
diseases develops as a complication when the patient has poor or delayed access to health 
care. Research is being conducted to better control these diseases, including vaccine devel-
opment. Concerning tropical diseases-associated kidney injury, the current “hot-topic” 
research is to detect this complication through novel biomarkers in order to provide an 
early and more specific management aiming to avoid or stop renal function loss and then 
prevent permanent renal insufficiency. Physicians attending patients with tropical diseases 
should always evaluate renal function, once renal involvement is frequent, and renal recov-
ery is possible if adequate management is provided.
Figure 1. General pathophysiology of kidney involvement in tropical infectious and parasitic diseases.
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